Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry
Open Access
- 27 October 2010
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (2), 382-390
- https://doi.org/10.1002/art.30117
Abstract
Objective To investigate disease activity, treatment response, and drug survival, and predictors thereof, among Danish patients with psoriatic arthritis (PsA) receiving their first treatment series with a tumor necrosis factor α (TNFα) inhibitor. Methods Patients with PsA were identified from a prospective nationwide rheumatologic database, the Danish biologics registry DANBIO, using data registered from 2000–2009. Information was obtained on the patients' clinical response to anti-TNFα treatment (defined as achievement of the American College of Rheumatology 20% [ACR20], ACR50, and ACR70 improvement criteria or a European League Against Rheumatism [EULAR] good response at least once during the first 6 months of treatment) and duration and rate of drug adherence (referred to as drug survival), as well as predictors thereof. Results Of 764 patients with PsA, 320 received adalimumab, 260 infliximab, and 184 etanercept. Median drug survival was 2.9 years, and 1-year and 2-year drug survival rates were 70% and 57%, respectively. Clinical parameters that showed improvement over 6 months were the C-reactive protein (CRP) level, Health Assessment Questionnaire score, and 28-joint Disease Activity Score. Male sex, CRP level >10 mg/liter, concomitant methotrexate use, and low patient health visual analog scale score at baseline were associated with longer drug survival. Improvement was achieved by 59%, 45%, 24%, and 54% of patients according to the ACR20, ACR50, ACR70 response criteria and EULAR good response, respectively. A CRP level >10 mg/liter was predictive of the improvement responses (odds ratio [OR] 2.6 for ACR20, OR 3.0 for ACR50, OR 3.6 for ACR70, and OR 2.2 for EULAR good response). Conclusion In these patients with PsA treated with their first TNFα inhibitor in clinical practice, high drug adherence and responder rates were observed. Moreover, increased levels of CRP at baseline were associated with both good treatment responses and continued treatment, which may be of clinical value in selecting the patients most likely to benefit from treatment with TNFα inhibitors.Keywords
This publication has 36 references indexed in Scilit:
- Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohortArthritis Care & Research, 2010
- An open-source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versionsRheumatology, 2009
- Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesionsAnnals Of The Rheumatic Diseases, 2009
- Treatment recommendations for psoriatic arthritisAnnals Of The Rheumatic Diseases, 2008
- Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexateAnnals Of The Rheumatic Diseases, 2006
- Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trialAnnals Of The Rheumatic Diseases, 2006
- Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formationAnnals Of The Rheumatic Diseases, 2006
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980